Literature DB >> 33849839

[Diagnostic value of serum amyloid A, procalcitonin and hypersensitive C-reactive protein for pulmonary tuberculosis complicated by pneumonia].

Y Jiang1, D Li1, S Lao1, P Xiao1.   

Abstract

OBJECTIVE: To assess the value of serum amyloid A (SAA), procalcitonin (PCT) and high-sensitivity C-reactive protein (hs-CRP) in the diagnosis of pulmonary tuberculosis (PTB) complicated by pneumonia.
OBJECTIVE: We collected serum samples from patients with pneumonia, patients with PTB, patients with PTB complicated by pneumonia and patients with PTB complicated by sepsis hospitalized in our hospital between April, 2019 and April, 2020. Serum levels of SAA, PCT and hs-CRP were tested, and receiver- operating characteristic (ROC) curves were used to evaluate their efficacy for predicting PTB with concurrent pneumonia and the possibility of differentiating PTB cases with pneumonia from those with sepsis using these 3 parameters. We also tested serum levels of SAA, PCT and hs-CRP in patients with PTB and those with PTB complicated by pneumonia admitted from May to July in 2020 to verify the accuracy of these 3 parameters combined for predicting the complication of PTB by pneumonia.
OBJECTIVE: Compared with the patients with PTB, the patients with pneumonia had significantly higher SAA and hs-CRP levels; serum SAA, PCT and hs-CRP levels were all significantly elevated in patients with PTB complicated by pneumonia (all P < 0.05). The levels of hs-CRP, white blood cell, D-dimer, FIB, APTT and neutrophil ratio were positively correlated with serum SAA level (all P < 0.05). The areas under the ROC curve (AUC) for serum SAA, PCT, and hs-CRP were 0.762, 0.781, and 0.800, respectively, and their combined AUC was 0.849 (all P < 0.001). For predicting PTB complicated by pneumonia, SAA combined with PCT had the same sensitivity (53.85%) and specificity (90.48%) as SAA, PCT and hs-CRP all combined. Serum SAA and PCT levels were similar between PTB patients with pneumonia and those with sepsis.
OBJECTIVE: Combined detection of serum SAA and PCT levels can be helpful in the diagnosis of PTB complicated by pneumonia, but neither of them is capable of differentiating the complication of pneumonia from sepsis possibly due to influence by abnormal blood coagulation.

Entities:  

Keywords:  hypersensitive C-reactive protein; pneumonia; procalcitonin; pulmonary tuberculosis; serum amyloid A

Mesh:

Substances:

Year:  2021        PMID: 33849839      PMCID: PMC8075783          DOI: 10.12122/j.issn.1673-4254.2021.03.20

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  11 in total

1.  Impact of procalcitonin-guided therapy for hospitalized community-acquired pneumonia on reducing antibiotic consumption and costs in Japan.

Authors:  Akihiro Ito; Tadashi Ishida; Hironobu Tokumasu; Yasuyoshi Washio; Akio Yamazaki; Yuhei Ito; Hiromasa Tachibana
Journal:  J Infect Chemother       Date:  2016-12-23       Impact factor: 2.211

2.  [Distribution and drug-resistance of bacteria in the lower respiratory tract in patients with tuberculosis and severe pneumonia receiving invasive mechanical ventilation].

Authors:  Suihua Lao; Juan Wang; Chaoxian Yu; Dexian Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2014-07

3.  Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis.

Authors:  Payam Nahid; Erin Bliven-Sizemore; Leah G Jarlsberg; Mary A De Groote; John L Johnson; Grace Muzanyi; Melissa Engle; Marc Weiner; Nebojsa Janjic; David G Sterling; Urs A Ochsner
Journal:  Tuberculosis (Edinb)       Date:  2014-02-07       Impact factor: 3.131

4.  Potential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting.

Authors:  Novel N Chegou; Gillian F Black; Andre G Loxton; Kim Stanley; Paulin N Essone; Michel R Klein; Shreemanta K Parida; Stefan H E Kaufmann; T Mark Doherty; Annemieke H Friggen; Kees L Franken; Tom H Ottenhoff; Gerhard Walzl
Journal:  BMC Infect Dis       Date:  2012-01-20       Impact factor: 3.090

5.  Discovery and Validation of a Six-Marker Serum Protein Signature for the Diagnosis of Active Pulmonary Tuberculosis.

Authors:  Mary A De Groote; David G Sterling; Thomas Hraha; Theresa M Russell; Louis S Green; Kirsten Wall; Stephan Kraemer; Rachel Ostroff; Nebojsa Janjic; Urs A Ochsner
Journal:  J Clin Microbiol       Date:  2017-08-09       Impact factor: 5.948

6.  A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis.

Authors:  Selena Ferrian; Claudia Manca; Sugnet Lubbe; Francesca Conradie; Nazir Ismail; Gilla Kaplan; Clive M Gray; Dorothy Fallows
Journal:  PLoS One       Date:  2017-05-02       Impact factor: 3.240

7.  Serum amyloid A, protein Z, and C4b-binding protein β chain as new potential biomarkers for pulmonary tuberculosis.

Authors:  Ting-Ting Jiang; Li-Ying Shi; Li-Liang Wei; Xiang Li; Su Yang; Chong Wang; Chang-Ming Liu; Zhong-Liang Chen; Hui-Hui Tu; Zhong-Jie Li; Ji-Cheng Li
Journal:  PLoS One       Date:  2017-03-09       Impact factor: 3.240

Review 8.  Biomarkers of Community-Acquired Pneumonia: A Key to Disease Diagnosis and Management.

Authors:  Elena N Savvateeva; Alla Yu Rubina; Dmitry A Gryadunov
Journal:  Biomed Res Int       Date:  2019-04-30       Impact factor: 3.411

9.  Evaluation of cytokine responses against novel Mtb antigens as diagnostic markers for TB disease.

Authors:  Dolapo O Awoniyi; Andrea Teuchert; Jayne S Sutherland; Harriet Mayanja-Kizza; Rawleigh Howe; Adane Mihret; Andre G Loxton; Jacob Sheehama; Desta Kassa; Amelia C Crampin; Hazel M Dockrell; Martin Kidd; Ida Rosenkrands; Annemieke Geluk; Tom H M Ottenhoff; P L A M Corstjens; Novel N Chegou; Gerhard Walzl
Journal:  J Infect       Date:  2016-06-14       Impact factor: 6.072

Review 10.  The Role of Procalcitonin in the Diagnosis of Meningitis: A Literature Review.

Authors:  Dimitrios Velissaris; Martina Pintea; Nikolaos Pantzaris; Eirini Spatha; Vassilios Karamouzos; Charalampos Pierrakos; Menelaos Karanikolas
Journal:  J Clin Med       Date:  2018-06-11       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.